blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2280693

EP2280693 - LIQUID AND FREEZE DRIED FORMULATIONS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  13.12.2013
Database last updated on 19.10.2024
Most recent event   Tooltip13.12.2013Application deemed to be withdrawnpublished on 15.01.2014  [2014/03]
Applicant(s)For all designated states
IPSEN PHARMA S.A.S.
65, Quai Georges Gorse
92100 Boulogne-Billancourt / FR
[N/P]
Former [2011/06]For all designated states
IPSEN PHARMA S.A.S.
65, quai Georges Gorse
91200 Boulogne-Billancourt / FR
Inventor(s)01 / NOURRISSON, Didier
42 route de Brézolles
28500 Vernouillet / FR
02 / MONDOLY, Nathalie
5 square Raphaël
F-78150 Le Chesnay / FR
03 / BENAMAR, Naziha
16 rue du chemin noir
F-78711 Mantes-La-Ville / FR
 [2011/06]
Representative(s)Audonnet, Nathalie
Ipsen Pharma S.A.S.
Direction de la Propriété Intellectuelle
65 quai Georges Gorse
92100 Boulogne-Billancourt / FR
[N/P]
Former [2011/06]Audonnet, Nathalie
Ipsen Pharma S.A.S. 65 quai Georges Gorse
92100 Boulogne-Billancourt / FR
Application number, filing date09727964.003.04.2009
[2011/06]
WO2009IB05441
Priority number, dateEP2008029033004.04.2008         Original published format: EP 08290330
[2011/06]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2009122288
Date:08.10.2009
Language:EN
[2009/41]
Type: A2 Application without search report 
No.:EP2280693
Date:09.02.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 08.10.2009 takes the place of the publication of the European patent application.
[2011/06]
Search report(s)International search report - published on:EP03.12.2009
ClassificationIPC:A61K9/19, A61K38/00, A61P35/00
[2011/06]
CPC:
A61K9/19 (EP,US); A61P25/00 (EP); A61P35/00 (EP);
A61P5/06 (EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2011/06]
TitleGerman:FLÜSSIGE UND GEFRIERGETROCKNETE FORMULIERUNGEN[2011/06]
English:LIQUID AND FREEZE DRIED FORMULATIONS[2011/06]
French:FORMULATIONS LIQUIDES ET LYOPHILISÉES[2011/06]
Entry into regional phase04.11.2010National basic fee paid 
04.11.2010Designation fee(s) paid 
04.11.2010Examination fee paid 
Examination procedure04.11.2010Examination requested  [2011/06]
11.01.2011Amendment by applicant (claims and/or description)
29.09.2011Despatch of a communication from the examining division (Time limit: M02)
28.11.2011Reply to a communication from the examining division
17.05.2013Despatch of a communication from the examining division (Time limit: M02)
30.07.2013Application deemed to be withdrawn, date of legal effect  [2014/03]
04.09.2013Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2014/03]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  29.09.2011
Fees paidRenewal fee
02.05.2011Renewal fee patent year 03
19.03.2012Renewal fee patent year 04
02.05.2013Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO9944604  (SHIONOGI & CO [JP], et al) [X] 1-13 * claims 1-27 *;
 [X]EP1762249  (ALTANA PHARMA AG [DE]) [X] 1-13 * examples 1-4 * * claims 1-21 *;
 [X]WO2005102274  (PFIZER PROD INC [US], et al) [X] 1-13 * example 1 *;
 [X]EP0443471  (YOSHITOMI PHARMACEUTICAL [JP], et al) [X] 1-13 * example 3 *;
 [X]WO0241919  (BYK GULDEN LOMBERG CHEM FAB [DE], et al) [X] 1-13 * examples 1-4 *;
 [X]GB2248550  (SANDOZ LTD [CH]) [X] 1-13 * examples 1-14 *;
 [X]WO03097101  (NOVUSPHARMA SPA [IT], et al) [X] 1-13 * claims 1-11 *;
 [Y]  - SAVEANU ALEXANDRU ET AL, "SOMATOSTATIN AND DOPAMINE-SOMATOSTATIN MULTIPLE LIGANDS DIRECTED TOWARDS SOMATOSTATIN AND DOPAMINE RECEPTORS IN PITUITARY ADENOMAS", NEUROENDOCRINOLOGY, S.KARGER, BASEL, CH, (20060101), vol. 83, no. 3-4, ISSN 0028-3835, pages 258 - 263, XP009085931 [Y] 11-13 * the whole document *

DOI:   http://dx.doi.org/10.1159/000095536
 [Y]  - ANDERSEN M, "The role of lanreotide Autogel(R) in the treatment of acromegaly", EXPERT REVIEW OF ENDOCRINOLOGY AND METABOLISM 200707 GB, (200707), vol. 2, no. 4, ISSN 1744-6651, pages 433 - 441, XP001538509 [Y] 11-13 * the whole document *

DOI:   http://dx.doi.org/10.1586/17446651.2.4.433
 [Y]  - JAQUET P ET AL, "BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.", JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION 2005, (2005), vol. 28, no. 11 Suppl International, ISSN 0391-4097, pages 21 - 27, XP009103539 [Y] 11-13 * the whole document *
by applicantWO0056365
    - "Stabilisation of Octastation, a somatostatin analogue. Preparation of freeze-dried products for parenteral injection", H. POURRAT, Biological and Pharmaceutical Bulletin, THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 18, pages 766 - 771
    - P JAQUET, "Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 153, no. 1, pages 135 - 141
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.